The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 27, 2023

Filed:

Sep. 09, 2016
Applicant:

University of Florida Research Foundation, Incorporated, Gainesville, FL (US);

Inventors:

Douglas Grant McFadden, Tempe, AZ (US);

Alfred S. Lewin, Gainesville, FL (US);

Alexandra Rose Lucas, Tempe, AZ (US);

Cristhian J. Ildefonso, Gainesville, FL (US);

Mohammed Masmudur Rahman, Chandler, AZ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/04 (2006.01); C12N 15/86 (2006.01); C07K 14/005 (2006.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01); C12N 7/00 (2006.01); A01K 67/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 9/0048 (2013.01); A61K 38/162 (2013.01); A61K 48/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 48/00 (2013.01); C12N 2710/24022 (2013.01); C12N 2750/14143 (2013.01);
Abstract

Disclosed are methods and compositions for preventing, treating, and/or ameliorating one or more symptoms of inflammation in a mammal. In particular, viral vectors and medicaments containing them are disclosed, which are useful in the prophylaxis, therapy, or amelioration of symptoms of one or more inflammatory-mediated mammalian diseases, such as age-related macular degeneration (AMD), arthritis, Bechet's disease, Best macular dystrophy, corneal inflammation, diabetic retinopathy, drusen formation, dry AMD, dry eye, geographic atrophy, glaucomaocular neovascularization, Lupus erythematosus, macular degeneration, Mallatia Leventinese and Doyne honeycomb retinal dystrophy, nephritis, ocular hypertension, ocular inflammation, recurrent uveitis, Sorsby fundus dystrophy, vasculitis, vitreoretinopathy, wet AMD, or related disorders. In exemplary methods, administration of a pharmaceutical composition comprising a recombinant viral vector that delivers a secretable and cell-penetrating M013 protein or peptide to a subject in need thereof facilitated treatment of particular human disorders such as AMD, ocular neovascularization, uveitis, and related inflammatory ocular disease.


Find Patent Forward Citations

Loading…